Search Results - "Buisseret, L"

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial by Buisseret, L., Pommey, S., Allard, B., Garaud, S., Bergeron, M., Cousineau, I., Ameye, L., Bareche, Y., Paesmans, M., Crown, J.P.A., Di Leo, A., Loi, S., Piccart-Gebhart, M., Willard-Gallo, K., Sotiriou, C., Stagg, J.

“…CD73 is an ecto-enzyme that promotes tumor immune escape through the production of immunosuppressive extracellular adenosine in the tumor microenvironment…”
Get full text

Immuno-oncology-101: overview of major concepts and translational perspectives by Allard, B., Aspeslagh, S., Garaud, S., Dupont, F.A., Solinas, C., Kok, M., Routy, B., Sotiriou, C., Stagg, J., Buisseret, L.

“…Cancer immunotherapy is demonstrating impressive clinical benefit in different malignancies and clinical oncologists are increasingly turning their attention…”
Get full text

Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials by Solinas, C, Ceppi, M, Lambertini, M, Scartozzi, M, Buisseret, L, Garaud, S, Fumagalli, D, de Azambuja, E, Salgado, R, Sotiriou, C, Willard-Gallo, K, Ignatiadis, M

“…Highlights • This is a meta-analysis of neoadjuvant randomized studies investigating TIL in HER2-positive breast cancer. • High baseline TIL are associated…”
Get full text

SYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) by Maurer, C., Eiger, D., Velghe, C., Aftimos, P.G., Maetens, M., Gaye, J., Paesmans, M., Ignatiadis, M., Piccart, M., Buisseret, L.

Get full text

The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab by Buisseret, L., Bareche, Y., Venet, D., Girard, E., Gombos, A., Emonts, P., Majjaj, S., Rouas, G., Serra, M., Debien, V., Agostinetto, E., Garaud, S., Willard-Gallo, K., Larsimont, D., Stagg, J., Rothé, F., Sotiriou, C.

“…Immune checkpoint blockade (ICB) in combination with chemotherapy improves outcome of patients with triple-negative breast cancer (TNBC) in metastatic and…”
Get full text

Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study by Nanda, R, Specht, J, Dees, E.C, Berger, R, Gupta, S, Geva, R, Pusztai, L, Pathiraja, K, Ray, A, Karantza, V, Buisseret, L

Get full text

The mutation spectrum in Holt-Oram syndrome by CROSS, STEPHEN J, CHING, YUNG-HAO, LI, QUAN YI, ARMSTRONG-BUISSERET, LINDSAY, SPRANGER, STEPHANIE, LYONNET, STANISLAW, BONNET, DAMIEN, PENTTINEN, MAILA, JONVEAUX, PHILIPPE, LEHEUP, BRUNO, MORTIER, GEERT, VAN RAVENSWAAIJ, CONNY, GARDINER, CAROL-ANNE, BROOK, J DAVID, NEWBURY-ECOB, RUTH

“…Of eight new sporadic cases studied, three have yielded mutations. [...]in the 34 familial cases studied by us, eight mutations have been identified, and six…”
Get full text

2274P Deep learning-based prediction of pathologic complete response to neoadjuvant therapy in breast cancer using H&E images and RNA-Seq in the IMMUcan study by Esposito, C., Garcia, A. Joaquin, Rediti, M., Penel, N., Oliveira, J., Goeminne, J-C., Fournel, P., Marques, A. Capela, Morfouace, M., Buisseret, L., Hong, H.S., Maussion, C.

Get full text

PO-1185 Targeting therapy-resistant metastatic clones with SBRT in oligoprogressive breast cancer by Van den Begin, R., Bellal, S., De Caluwé, A., Aftimos, P., Paquier, Z., Gebhart, G., Buisseret, L., Martinive, P., Lefranc, F., Van Gestel, D.

Get full text

165P Immune characterization of the de novo oligometastatic breast cancer by Chretien, S., Buisseret, L., Wang, X., Rouas, G., Kotecki, N., Garaud, S., Mailliez, A., Larsimont, D., Rothé, F., Sotiriou, C.

Get full text

44P The hematologic toxicities of chemo-immunotherapy compared to chemotherapy alone: A systematic review and meta-analysis by Eiger, D., Agostinetto, E., Caparica, R., Franzoi, M.A., Brandão, M., Buisseret, L., de Caluwé, A., Gimenes, D., Simon, S.D., Pondé, N.F., de Azambuja, E.

Get full text

98P Neo-CheckRay, radiation therapy and adenosine pathway blockade to potentiate benefit of immuno-chemotherapy in early stage luminal B breast cancer: Results of the safety run-in phase by De Caluwe, A., Romano, E., Poortmans, P., Gombos, A., Laragione, A., Agostinetto, E., Nader Marta, G., Picchia, S., Vandekerkhove, C., Ameye, L., Craciun, L., Veys, I., Van Gestel, D., Larsimont, D., Sotiriou, C., Piccart, M., Ignatiadis, M., Buisseret, L.

Get full text

72TiP ROSALINE: A phase II, single-arm, neoadjuvant study of targeting ROS1 in combination with endocrine therapy (ET) in invAsive Lobular carcINoma of the brEast by Agostinetto, E., Paesmans, M., Ameye, L., Veys, I., Buisseret, L., Neven, P., Taylor, D., Fontaine, C., Duhoux, F.P., Canon, J-L., Denys, H., Coussy, F., Chakiba, C., Pistilli, B., Piccart, M., Ignatiadis, M., Aftimos, P.G.

Get full text

LBA17 Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC) by Buisseret, L., Loirat, D., Aftimos, P.G., Punie, K., Maurer, C., Debien, V., Goncalves, A., Ghiringhelli, F., Taylor, D., Clatot, F., van den Mooter, T.F.A., Ferrero, J-M., Bonnefoi, H., Canon, J-L., Duhoux, F.P., Bazan, F., Kristanto, P., de Azambuja, E., Ignatiadis, M., Piccart, M.

Get full text

84TiP Neo-CheckRay: Radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer: A randomized phase II trial by De Caluwe, A., Buisseret, L., Poortmans, P., Sotiriou, C., Larsimont, D., Van Gestel, D., Laragione, A., Desmet, A., Van Den Begin, R., Philippson, C., Eiger, D., Piccart, M., Romano, E., Ignatiadis, M.

Get full text

195TiPSYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) by Maurer, C, Eiger, D, Velghe, C, Aftimos, P G, Maetens, M, Gaye, J, Paesmans, M, Ignatiadis, M, Piccart, M, Buisseret, L

Get full text

Abstract P4-06-03: Unravelling triple-negative breast cancer tumor microenvironment heterogeneity using an integrative multiomic analysis by Bareche, Y, Buisseret, L, Gruosso, T, Girard, E, Venet, D, Dupont, F, Desmedt, C, Park, M, Rothé, F, Stagg, J, Sotiriou, C

“…Abstract Introduction: Triple negative breast cancer (TNBC) constitute 10-20% of all breast cancers and is associated with a worse prognosis and limited…”
Get full text

188P Impact of HIV infection (HIV+) on baseline characteristics and survival of breast cancer (BC) patients (pts): A systematic review and meta-analysis by Brandão, M.D.R.A., Bruzzone, M., Franzoi, M.A., de Angelis, C., Eiger, D., Caparica, R., Dauby, N., Ceppi, M., Piccart, M., Carrilho, C., Lunet, N., Buisseret, L., de Azambuja, E., Lambertini, M.

Get full text

348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC) by Eiger, D., Maurer, C., Brandao, M., Aftimos, P.G., Punie, K., Taylor, D., Van den Mooter, T., Poncin, R., Canon, J-L., Duhoux, F., Casert, V., Clatot, F., Velghe, C., Craciun, L., Paesmans, M., de Azambuja, E., Ignatiadis, M., Larsimont, D., Piccart, M., Buisseret, L.

Get full text

19P The prognostic value of soluble CD73 in advanced triple-negative breast cancer: An exploratory analysis of the SYNERGY trial by Zoë, D., Kristanto, P., Catteau, X., Vincent, D., Debien, V., Agostinetto, E., Stagg, J., Salgado, R.F., Larsimont, D., Sotiriou, C., Rothé, F., Buisseret, L.

Get full text